Merck & Co., Inc.’s Keytruda is on a bit of a losing streak at the US Food & Drug Administration.
The blockbuster anti-cancer therapy was turned down for a new indication in early stage breast cancer earlier this year. Merck...
Merck has pulled one Accelerated Approval indication for Keytruda already this year, and a second may have to be withdrawn as well. That will leave the product with 27 indications in the US – unless, of course, more are approved before the AA indications are formally pulled.
Merck & Co., Inc.’s Keytruda is on a bit of a losing streak at the US Food & Drug Administration.
The blockbuster anti-cancer therapy was turned down for a new indication in early stage breast cancer earlier this year. Merck...